Integrated Peptide Drug Discovery Platform

120 dedicated scientists operating the broadest synthesis technology base of any India-based peptide CRO — solid phase, liquid phase, hybrid, TAG-assisted, and native chemical ligation.

• Linear, branched, cyclic, stapled & macrocyclic peptides
• Conformationally constrained designs (on-resin & off-resin)
• Click chemistry, multiple disulfides, lactams
• Peptide conjugates (lipid, steroid, SM, carbohydrate, PEG)
• Fmoc, Z- & t-Boc chemistry types
• Protein synthesis via NCL and KAHA ligation
• Difficult peptides via solubility tags
• 2–150 amino acids, mg to kg scale, >98% purity
• 500+ unnatural amino acid building blocks in stock
• 40 dedicated analytical scientists + 24×7 purification
• Automated: PTI Prelude, CEM Liberty Blue, Biotage Alstra, SONATA XT

PeptARx supports virtually every class of therapeutic and research-grade peptide, including:

• Linear, branched, cyclic, bi-cyclic, and stapled peptides
• Macrocyclic peptides and conformationally constrained designs (on-resin and off-resin cyclisation)
• Peptide conjugates — lipid, steroid, small molecule, carbohydrate, PEG, DOTA, fluorophore
• Peptide-drug conjugates (PDCs), peptide-PMO (PPMO), and peptide-oligonucleotide conjugates (POC)
• Long peptides and synthetic protein fragments (up to 150+ amino acids) via NCL and KAHA ligation
• Peptidomimetics and N-alkylated, β-amino acid, and glycosylated amino acid-containing sequences

We operate across all three major synthesis platforms — solid phase, liquid phase, and hybrid — using Fmoc, Z- and t-Boc chemistries. With 500+ unnatural amino acids catalogued in-house, we can incorporate non-standard building blocks without sourcing delays that add weeks to competitor timelines. Scale ranges from milligrams to >500 g (non-GMP), with purities routinely exceeding 98%.

The most common reason peptide drug candidates fail is not poor synthesis — it is poor druggability. Solubility issues, metabolic instability, low permeability, and aggregation-related problems frequently surface late in the development cycle, after months of synthesis and testing have already been completed. By that point, significant budget and time have been invested in a molecule that may never become a viable drug.

PeptARx was designed specifically to catch these failures early. Because our peptide chemists work alongside DMPK scientists (who assess solubility, metabolic stability, permeability, and plasma stability) and ADS scientists (who run target engagement and functional assays) at the same site and within the same project team, we can flag formulation-level problems during the synthesis phase itself. This "formulation-aware" approach means clients know within weeks — not months — whether their candidate has a viable path forward, saving both time and development budget.

Peptide candidates require specialised ADME assessment that differs from standard small-molecule protocols. Applying conventional small-molecule DMPK methodologies to peptides often generates misleading results — a common pitfall when synthesis and DMPK are handled by different vendors. Aragen's 109-person DMPK team delivers peptide-relevant profiling with a turnaround of under 7 working days, including:

• Solubility screening (pION, kinetic, thermodynamic, biorelevant media including FaSSIF, FeSSIF, and FaSSGF)
• Permeability assessment (PAMPA-GIT, PAMPA-BBB, Caco-2, MDCK, MDCK-MDR1)
• Metabolic stability in microsomes and hepatocytes across five species (human, mouse, rat, dog, monkey)
• Plasma protein binding, plasma stability, and whole blood partitioning
• CYP inhibition (8 isoforms), CYP induction (PXR, CAR, AHR), and transporter assays (ABC/SLC T7 panel)
• In vivo pharmacokinetics in rodent and non-rodent species

Our Biomek i7 automated workstations process 150 compounds per assay (3× manual throughput), and RAPID FIRE MS/MS enables a 5-day assay-to-report cycle — ensuring that DMPK data never becomes the bottleneck in your peptide discovery timeline.

Yes — metabolic disease and GLP-1 programs are one of PeptARx's strongest therapeutic focus areas. The GLP-1 revolution has created enormous demand for peptide synthesis and characterisation services, from semaglutide analogues to next-generation dual and triple agonists (GLP-1/GIP, GLP-1/GIP/glucagon).

What sets Aragen apart in this space is the depth of our biosafety team's experience with GLP-1 molecules. Our team has conducted bioanalytical studies on 20+ GLP-1 molecules — covering both innovator and biosimilar programs — making us one of the leaders in India for metabolic peptide safety assessment. This means we can offer a true end-to-end metabolic peptide workflow: from peptide synthesis through DMPK profiling to GLP toxicology, all under one roof. Clients do not need to transfer their program between multiple vendors at the critical transition from discovery into preclinical safety.

IP protection is paramount for peptide drug discovery, where the molecular sequence itself is often the client's most valuable asset. Aragen has maintained robust IP protection protocols across 23 years of drug discovery partnerships, serving 400+ global customers with a 90%+ repeat rate — a metric that reflects deep client trust.

Our IP protection infrastructure includes: fully digital operations with 21 CFR Part 11-compliant electronic lab notebooks (eLNB), strict documentation protocols for data integrity and confidentiality, and the InCoRe digital platform that provides real-time project transparency while maintaining data security. As a Frost & Sullivan 2024 Global Customer Value Leadership Award recipient, our quality and governance standards are independently validated.

Critically, Aragen has zero BIOSECURE Act exposure. As an India-headquartered CRDMO, our operations are not affected by the US legislation restricting collaboration with certain China-based service providers. For pharma and biotech companies currently diversifying their CRO panels away from China-based peptide providers, Aragen offers a geopolitically neutral alternative with up to 60% cost advantage versus Western CROs.

PeptARx supports the full discovery-to-preclinical scale continuum without requiring technology transfer to a separate manufacturing partner. Our scale range covers:

• Discovery scale: Milligram quantities for SAR studies, assay development, and lead identification
• Optimisation scale: Hundreds of milligrams for in vivo efficacy studies, DMPK profiling, and formulation development
• Preclinical / IND-enabling scale: >500 g batches at >98% purity (single impurity <0.5%), scalable toward kilogram quantities for toxicology studies

This is enabled by our infrastructure: automated synthesisers (CEM Liberty Blue, Biotage Alstra, PTI Prelude) for discovery scale, SONATA/XT reactors and 10L jacketed reactors for scale-up, and our 24/7 preparative HPLC purification capacity supporting peptides from 1,000 to 20,000 Da. By keeping the entire program within PeptARx — from first milligram synthesis through to IND-enabling batches — we eliminate the technology transfer risks and timeline delays that frequently occur when transitioning peptides between discovery CROs and manufacturing CDMOs.